A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance
GSA 2025 Abstract
Abstract
It has been postulated that metformin may extend healthspan but no long-term trials have been done in humans. We conducted a randomized, double-blinded, placebo-controlled clinical trial of metformin to reduce frailty in older adults (≥65 years) with glucose intolerance.